4D pharma plc (LON:DDDD – Get Rating) shares were up 1% during mid-day trading on Friday . The company traded as high as GBX 54.90 ($0.72) and last traded at GBX 50.50 ($0.66). Approximately 5,496,229 shares changed hands during mid-day trading, an increase of 71% from the average daily volume of 3,219,667 shares. The stock […]
4D pharma encouraged after additional analysis of IBS drug data
Presented as a poster at the medical and scientific conference, Digestive Disease Week, the new analysis builds on the top-line results released last October
4D pharma PLC (LON:DDDD, NASDAQ:LBPS) said it has provided a more detailed analysis of its Live Biotherapeutic, Blautix, which is both significant and supportive of its continued development as an irritable bowel syndrome treatment.
The data, presented as a poster at the medical and scientific conference Digestive Disease Week, builds on the top-line results released last October.
The poster revealed “strong and statistically significant activity” on the key symptom of bowel habit, which 4D describes as a “potential approvable primary endpoint per regulatory guidelines”.
24 May 2021 | 08:43am
StockMarketWire.com - Pharmaceutical company 4D Pharma provided additional positive data from its completed phase 2 trial of LBP Blautix to treat irritable bowel syndrome with constipation or with diarrhea. Further analysis of the data has revealed strong and statistically significant activity on the key symptom of bowel habit, a potential approvable primary endpoint per regulatory guidelines, the company said.
4D pharma previously announced topline efficacy and safety results from the trial, conducted in the US, UK and Ireland, in October 2020.
In the post-hoc sub-group analysis, statistically significant improvements in bowel habit in IBS-D, and a strong effect nearing significance in IBS-C were seen in patients across all geographic regions.
4D Pharma teams up with Parkinson’s UK
It is setting up a patient advisory board with the non-profit group made up of people living with the disease that will provide a “valuable patient-centric perspective” on a potential treatment Actor Michael J Fox lives with the debilitating disease
4D Pharma PLC (LON:DDDD; NASDAQ:LBPS) said it will collaborate with Parkinson’s UK as it continues to advance a drug that treats neurodegenerative conditions such as Parkinson s into clinical trials.
It is setting up a patient advisory board (PAB) with the non-profit group made up of people living with the disease that will provide a “valuable patient-centric perspective” on the potential treatment.